EuroBiotech: More Articles of Note


> Hansa Biopharma shared long-term data on the use of imlifidase in kidney transplant patients. The study linked the drug to two-year graft survival of 89%. Statement 

> Arix Bioscience named Roberto Iacone as entrepreneur in residence. Iacone, who joins from Versant Ventures, will focus on company creation. Release 

> Compugen presented interim data from a phase 1 trial of anti-PVRIG antibody COM701. Two patients, one in the COM701 monotherapy arm, another in the Opdivo combination cohort, have had confirmed partial responses. Statement 

> Zelluna Immunotherapy teamed up with Karolinska Institutet to develop T cell receptor-guided natural killer cell therapies. Evren Alici, head of the gene and cell therapy group at Karolinska, will work on the multi-year research program. Release 

> Freeline received European orphan drug designation for Fabry disease prospect FLT190. Statement 

> Medigene secured an option to license immune cell enhancers under the terms of a collaboration with Phio Pharmaceuticals. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.